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 Combinatorial targeted therapies are more effective in treating cancer by blocking by-pass mechanisms or 
inducing synthetic lethality. However, their clinical application is hampered by resistance and toxicity. To meet this 
important challenge, we developed and tested a novel concept of biomarker-guided sequential applications of vari-
ous targeted therapies using ErbB2-overexpressing/PTEN-low, highly aggressive breast cancer as our model. Strik-
ingly, sustained activation of ErbB2 and downstream pathways drives trastuzumab resistance in both PTEN-low/
trastuzumab-resistant breast cancers from patients and mammary tumors with intratumoral heterogeneity from 
genetically-engineered mice. Although lapatinib initially inhibited trastuzumab-resistant mouse tumors, tumors by-
passed the inhibition by activating the PI3K/mTOR signaling network as shown by the quantitative protein arrays. 
Interestingly, activation of the mTOR pathway was also observed in neoadjuvant lapatinib-treated patients manifest-
ing lapatinib resistance. Trastuzumab + lapatinib resistance was effectively overcome by sequential application of a 
PI3K/mTOR dual kinase inhibitor (BEZ235) with no significant toxicity. However, our p-RTK array analysis dem-
onstrated that BEZ235 treatment led to increased ErbB2 expression and phosphorylation in genetically-engineered 
mouse tumors and in 3-D, but not 2-D, culture, leading to BEZ235 resistance. Mechanistically, we identified ErbB2 
protein stabilization and activation as a novel mechanism of BEZ235 resistance, which was reversed by subsequent 
treatment with lapatinib + BEZ235 combination. Remarkably, this sequential application of targeted therapies guid-
ed by biomarker changes in the tumors rapidly evolving resistance doubled the life-span of mice bearing exceedingly 
aggressive tumors. This fundamentally novel approach of using targeted therapies in a sequential order can effec-
tively target and reprogram the signaling networks in cancers evolving resistance during treatment. 
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Introduction
In the era of personalized medicine, targeted cancer 
therapies have improved the clinical outcome in many 
cancer types including breast cancer. Almost 20% of 
breast cancers overexpress the HER2/ErbB2 receptor 
tyrosine kinase (RTK) [1]. Trastuzumab (also named 
Herceptin), a humanized monoclonal antibody against the 
extracellular domain of HER2/ErbB2 [2], has been revo-
lutionary in treating patients with ErbB2-overexpressing 
tumors in neoadjuvant [3], adjuvant [4] and metastatic 
settings [5]. After the success of trastuzumab, other drugs 
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have been developed to target ErbB2 (e.g., pertuzumab, 
T-DM1) or to other members of the ErbB family of re-
ceptors (e.g., EGFR). Similarly, lapatinib, a dual tyrosine 
kinase inhibitor which targets the ATP-binding pockets of 
both ErbB2 and EGFR, has been approved by the FDA for 
treating ErbB2-overexpressing, trastuzumab-refractory 
breast cancers [6]. However, a major obstacle in the 
clinic for the success of trastuzumab and these other tar-
geted agents is primary (or de novo) and secondary (or 
acquired) resistance. Therefore, it is essential to identify 
biomarkers and mechanisms of resistance to select sub-
populations of patients who are likely responders and 
to develop new regimens or agents that target resistance 
pathways to reverse resistance.
Various mechanisms of resistance have been proposed 
for both de novo and acquired trastuzumab resistance, 
e.g., activation of other RTKs (e.g., ErbB3 or IGF-1R), 
steric hindrance of ErbB2-trastuzumab interaction by 
glycoproteins (e.g., MUC4), inhibition of trastuzumab 
binding to ErbB2 by cleavage of ErbB2 extracellular 
domain (p95ErbB2) and activation of PI3K pathway 
or SRC [7, 8]. We previously demonstrated that loss of 
the phosphatase and tensin homolog (PTEN), a nega-
tive regulator of the PI3K/AKT pathway, confers de 
novo trastuzumab resistance in ErbB2-overexpressing 
breast cancer [9]. Later, PTEN was identified to be the 
only modulator of trastuzumab response in an RNA in-
terference-based functional screen for genes involved in 
trastuzumab resistance in breast cancer [10]. Importantly, 
the tumor suppressor PTEN could be lost in up to 50% of 
breast cancers due to mutations, loss of heterozygosity or 
epigenetic modifications [11]. PTEN deficiency acceler-
ates the development of multifocal and highly metastatic 
mammary tumors with ErbB2/neu overexpression in 
mice [12] and the resulting tumors are highly aggressive 
and refractory to treatment with trastuzumab [13]. There-
fore, novel therapies are urgently needed to overcome 
trastuzumab resistance in this patient subpopulation hav-
ing highly aggressive disease. 
To this end, combinatorial targeted therapies hold great 
promise through blocking the potential by-pass mecha-
nisms or inducing synthetic lethality. We have recently 
shown that targeting SRC, a key node in the trastuzumab 
resistance network, by a SRC inhibitor (saracatinib) in 
combination with trastuzumab overcomes trastuzumab 
resistance from multiple resistance mechanisms, includ-
ing PTEN loss [14]. Additionally, we demonstrated that 
in two different genetically-engineered mouse models of 
trastuzumab resistance (mammary gland-specific ErbB2/
neu transgenic and PTEN knockout), an Akt inhibitor 
(triciribine) synergizes with trastuzumab in tumor inhibi-
tion [13]. Targeting the PI3K pathway in combination 
with trastuzumab has also been reported to overcome 
trastuzumab resistance in other models [15]. Although 
initially successful, these combinatorial regimens rapidly 
develop resistance and are often too toxic for clinical 
usage [16]. Therefore, innovative strategies of applying 
targeted agents with high efficacy but low toxicity are 
crucial in tackling the challenge.
Here, we developed and experimentally tested a novel 
strategy of employing targeted agents for potentially 
highly effective clinical cancer therapy: using arising 
biomarkers in an ErbB2-overexpressing cancer evolving 
therapy resistance to guide subsequent applications of 
various combinatorial targeted therapies in a sequential 
manner to inhibit the constantly changing resistant sig-
nals in the cancer during targeted therapies. We report 
that this strategy of sequential application of various 
combinatorial targeted therapies reprogrammed the sig-
naling networks in cancer evolving therapy resistance 
and yielded cancer vulnerabilities compared to using all 
targeted agents at once. Remarkably, this fundamentally 
novel approach doubled the survival time of mice bear-
ing highly aggressive, therapy-refractory ErbB2-overex-
pressing tumors. It is anticipated that this strategy can be 
rapidly translated into the clinic to benefit cancer patients 
who have highly aggressive and therapy-resistant tumors.
Results
Biomarker analyses denote activation of multiple ErbB2 
downstream pathways in PTEN-low/trastuzumab-resis-
tant tumors that are inhibited by lapatinib
To explore novel strategies of employing targeted 
agents for highly effective cancer therapy that reverse 
resistance and reduce toxicity, we focused on HER2/
ErbB2-overexpressing breast cancers. We previously 
found that PTEN loss confers resistance to trastuzumab 
in patients with ErbB2-overexpressing breast cancers 
[9]. Therefore, we initially compared the gene expression 
profiles and analyzed signaling events in breast cancers 
from PTEN-low/trastuzumab-resistant versus PTEN-
normal/trastuzumab-sensitive patients who had neoadju-
vant trastuzumab plus chemotherapy treatment (Figure 
1A) [17]. First, we identified the differentially expressed 
genes from cDNA microarray of the fine-needle aspira-
tion specimens between these two groups (Supplementary 
information, Table S1) [17], and then determined the 
pathways in which these genes are enriched using Inge-
nuity Pathway Analysis (IPA) (Figure 1B and Supple-
mentary information, Table S2). As expected, the PI3K 
pathway signature was significantly increased in PTEN-
low/trastuzumab-resistant tumors. Additionally, we 
identified multiple pathways (e.g., MAPK, and p70S6K) 
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significantly activated in PTEN-low/trastuzumab-resis-
tant tumors (P < 0.05). Interestingly, we also observed a 
clear trend for increased expressions of EGF and ErbB2-
ErbB3 signaling in this small cohort of PTEN-low/trastu-
zumab-resistant patients (Figure 1B). 
We next examined whether these signatures detected 
in patients can be recapitulated in PTEN loss-mediated 
trastuzumab-resistant mouse models to be used for pre-
clinical testing of new strategies of targeted therapies. 
We crossed HER2/neu-overexpressing (MMTV-neu-
IRES-cre, or NIC) mice with PTENfl/fl mice (PTEN−/−/
NIC), which developed highly aggressive neu-overex-
pressing/PTEN-deficient and trastuzumab-resistant mam-
mary tumors with median survival of 45 days [13]. We 
applied a quantitative proteomics approach of reverse 
phase protein array (RPPA, containing > 150 antibodies) 
[18] on lysates of mammary tumors from the PTEN−/−/
NIC mice and compared it to the PTEN+/+/NIC (PTEN 
wild type) tumors. As with patient tumors, tumors of the 
PTEN−/−/NIC mice had activation of not only the PI3K 
Figure 1 Lapatinib alone or combined with anti-ErbB2 antibody Ab7.16.4 increases survival of PTEN−/−/NIC trastuzumab-
resistant mice. (A) Treatment scheme of 14 ErbB2-positive breast cancer patients. Patients were classified into two groups: 
trastuzumab sensitive with high PTEN level (PCR/high PTEN) (n = 7) and trastuzumab resistant with normal PTEN level (RD/
low PTEN) (n = 7). (B) Identification of significantly different canonical pathways between trastuzumab-resistant and -sensi-
tive patients using IPA. Threshold is at P < 0.05 (dotted yellow line); y axis is –log of the P-value. (C) Western blot of PTEN−/−/
NIC tumor lysates from mice treated with different drugs for 3 days. (D) WST-1 cell proliferation assay comparing proliferation 
of BT474.shPTEN cells after drug treatment for 72 h (Ttzm: trastuzumab and T + L: trastuzumab plus lapatinib). Inset shows 
western blot validation of PTEN knockdown. **P < 0.01, ***P < 0.001 by two-tailed t-test. (E) Survival analysis of the PTEN−/−/
NIC mice treated with different drugs or combinations. P < 0.001 (by log-rank test) is between Ab7.16.4 and lapatinib; P = 0.008 
is between lapatinib and Ab7.16.4 + lapatinib. (F) Left, tumor weight (mean ± SEM) of mice treated with vehicle, 7.16.4 mAb 
(Ab), lapatinib, or combination for 3 weeks. ***P < 0.001 by two-tailed t-test. (G) Ki-67 staining of tumor tissue obtained from 
mice treated with different drugs or their combination. Scale bar indicates 20 µm. **P < 0.01, ***P < 0.001 by two-tailed t-test.
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Figure 2 Resistance to Ab7.16.4 + lapatinib combination develops through activation of PI3K/mTOR pathways in PTEN−/−/
NIC mice and mTOR gene signature is enriched in lapatinib-resistant patients. (A) Tumor volume measurements at different 
time points for transplant mice treated with Vehicle or Ab + lapatinib. Mice were sacrificed on day 9 (803 and 809) or day 13 
(802 and 828). 803 and 809 were sensitive whereas 828 was resistant to Ab + lapatinib. (B) RPPA analysis showing expres-
sion or phosphorylation of proteins downregulated in Ab + lapatinib-sensitive tumors and upregulated or not affected in Ab + 
lapatinib-resistant tumors compared to control. PI3K/mTOR pathway components are bolded. (C) Western blot analysis of Ab 
+ lapatinib-sensitive and -resistant tumors shown in A. (D) Treatment scheme of ErbB2-positive breast cancer patients treat-
ed with neoadjuvant lapatinib followed by trastuzumab + docetaxel. Gene expression profiling was done with RNA isolated 
from tumors before and after lapatinib treatment (“start” and “week 6”). (E) GSEA of tumors from lapatinib-resistant patients. 
Genes upregulated upon mTOR inhibition by everolimus were significantly downregulated. (F) Western blot analysis of pa-
rental (BT474.Par) and lapatinib-resistant (BT474.LapR) cells treated with DMSO or lapatinib (1 µM) over 3 days.
pathway, but also ERK1/2, p70S6K, S6K, 4EBP1, Stat3 
and SRC, as shown by RPPA and validated by western 
blot (Supplementary information, Figure S1A and S1B). 
Importantly, PTEN loss in mammary tumors of PTEN−/−/
NIC mice also resulted in hyper-phosphorylation of the 
ErbB2/neu RTK (Supplementary information, Figure 
S1C), which resembles the trend in patients (Figure 1B). 
Based on (a) this enhanced ErbB2 and multiple ErbB2 
downstream signaling pathways in tumors of PTEN−/−/
NIC mice and PTEN-low/trastuzumab-resistant patients, 
and (b) the clinical use of lapatinib to treat trastuzumab-
refractory breast cancers, we tested whether lapatinib can 
effectively inhibit activation of multiple ErbB2 down-
stream pathways and impede tumorigenesis of PTEN−/−/
NIC mice. Indeed, lapatinib inhibited the phosphoryla-
tion of ErbB2 targets Akt, S6 and Erk1/2 compared to 
Ab7.16.4, the rodent equivalent of trastuzumab (Figure 
1C) [19]. Significantly, combination of lapatinib with 
Ab7.16.4 inhibited the Akt, S6 and Erk1/2 phosphoryla-
tion more effectively than lapatinib alone. We also tested 
whether lapatinib inhibits the proliferation of an ErbB2-
overexpressing BT474 human breast cancer cell line 
with stable PTEN knockdown (BT474.shPTEN), which 
is trastuzumab resistant [14]. As in the mouse model, 
lapatinib inhibited the BT474.shPTEN cell growth, 
and the combination of trastuzumab with lapatinib is 
more effective than lapatinib alone (Figure 1D). Impor-
tantly, lapatinib significantly increased survival of the 
Ab7.16.4-resistant PTEN−/−/NIC mice (P < 0.001), and 
lapatinib plus Ab7.16.4 further increased the survival 
of these mice than lapatinib alone (P = 0.008) (Figure 
1E). Lapatinib alone or combination treatment reduced 
tumor weight after three weeks of treatment compared to 
vehicle or Ab7.16.4 (Figure 1F). Furthermore, lapatinib 
alone or combination treatment dramatically inhibited 
cell proliferation (Figure 1G), without affecting apop-
tosis of tumors in PTEN−/−/NIC mice (Supplementary 
information, Figure S2). Taken together, our biomarker 
analyses indicated that 1) PTEN loss leads to activation 
of multiple ErbB2 downstream pathways in PTEN-low/
trastuzumab-resistant patient tumors and in PTEN−/−/NIC 
mouse mammary tumors with conferring trastuzumab re-
sistance; 2) the use of lapatinib, alone or in combination 
with trastuzumab, targets these ErbB signaling events 
and overcomes PTEN loss-mediated trastuzumab resis-
tance. 
Activation of PI3K/mTOR pathways in tumors resistant 
to Ab7.16.4 + lapatinib combination
Although lapatinib was a rational choice with effi-
cacy in treating PTEN-low/trastuzumab-resistant tumors 
based on the biomarker analysis (Figure 1), lapatinib in 
combination with trastuzumab provides only 4.5 months 
of survival advantage [20], which is also reflected by the 
tumor relapse in PTEN−/−/NIC mice (Figure 1E). There-
fore, we next aimed to identify biomarkers of resistance 
to lapatinib + trastuzumab treatment and test therapies 
to effectively overcome the resistance. To this end, we 
employed a tumor transplantation model by transplant-
ing mammary tumors from the PTEN−/−/NIC donor mice 
to mammary fat pads (MFPs) of recipient syngeneic 
mice (in FVB background) to facilitate timely testing of 
different therapies (Supplementary information, Figure 
S3A). The tumor transplants faithfully recapitulated both 
molecular alterations (activation of signaling proteins, 
Supplementary information, Figure S3B) and biologi-
cal properties (aggressive growth rate and trastuzumab 
resistance, Supplementary information, Figure S3C) of 
the donor PTEN−/−/NIC mice. Similar to the tumors of 
the donor mice, most transplants initially responded to 
Ab7.16.4 + lapatinib therapy with reduced cell prolifera-
tion (Supplementary information, Figure S3D and S3E) 
but no significant difference in apoptosis (Supplemen-
tary information, Figure S3F), whereas some were non-
responding (Supplementary information, Figure S3D-
S3F). Thus, this transplantation model is appropriate for 
testing biomarkers and targeted therapies for overcoming 
Ab7.16.4 + lapatinib resistance.
We treated mice bearing tumor transplants with 
Ab7.16.4 + lapatinib combinatorial therapy and followed 
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their tumor growth. All transplants initially responded 
to therapy with reduced cell proliferation, but some ac-
quired resistance later and tumors resumed growth (Fig-
ure 2A and Supplementary information, Figure S3D). 
Accordingly, we classified transplants into sensitive and 
resistant groups based on tumor volume change. We per-
formed RPPA to compare tumor biomarkers in these two 
groups and the control-treated group. Clearly, Ab7.16.4 
+ lapatinib-sensitive tumors had reduced levels of p-
AKT, p-PRAS40, p-mTOR, p-S6 and p-4EBP compared 
to the control group (Figure 2B and Supplementary in-
formation, Table S3). However, in Ab7.16.4 + lapatinib-
resistant tumors, phosphorylation levels of all these pro-
teins were similar to, or higher than, those in the control 
group, indicating that PI3K and downstream mTOR path-
ways remained active in resistant tumors. The RPPA data 
were further validated by western blots in tumor lysates 
from additional mice (Figure 2A-2C). These analyses 
indicated that the activation of the PI3K/mTOR pathway 
is potentially a critical molecular event (a biomarker) of 
Ab7.16.4 + lapatinib resistance in PTEN−/−/NIC tumors.
The mTOR pathway is upregulated in lapatinib-resistant 
patient tumors and activated in lapatinib-resistant hu-
man breast cancer cells
To test the clinical relevance of our findings from 
transplant models, we obtained patient tumor mRNAs 
isolated before and after 6 weeks of neoadjuvant single 
agent lapatinib treatment and examined their gene ex-
pression profiles [21] (Figure 2D). The pathological 
response to treatment was evaluated after subsequent 
treatment with trastuzumab and docetaxel for 12 weeks 
and grouped into pathological complete response or near-
complete response (pCR/pNCR) versus non-responders 
(NRs). After identifying differentially expressed genes 
between these two groups, we examined whether PI3K 
or mTOR pathway gene signatures were increased in the 
NR group. Gene set enrichment analysis (GSEA) [22] 
revealed that tumors of NR patients had a significant 
downregulation of genes which were upregulated upon 
mTOR inhibition by everolimus (RAD001) [23] (Figure 
2E). This suggests that the mTOR gene signature is up-
regulated in resistant tumors of patients and may play an 
important role in lapatinib + trastuzumab resistance, sim-
ilar to that observed in the transplant model (Figure 2B 
and 2C). To test whether the mTOR pathway is activated 
in lapatinib + trastuzumab-resistant human breast cancer 
cells, we selected lapatinib-resistant BT474 human breast 
cancer cell line (BT474.LapR) by continuous exposure 
of BT474 cells to lapatinib over 9 months. These BT474.
LapR cells are also highly resistant to trastuzumab 
(Supplementary information, Figure S3G). We treated 
the cells with lapatinib for 1, 2, and 3 days and analyzed 
PI3K/mTOR pathway activation by western blot. Indeed, 
the lapatinib + trastuzumab-resistant BT474.LapR cell 
line showed a higher and sustained phosphorylation of 
Akt and S6 compared to the parental line (BT474.Par) 
(Figure 2F). Taken together, these data indicate that 
PI3K and/or its downstream mTOR pathway is activated 
in lapatinib + trastuzumab-resistant human breast can-
cers and cell lines, further supporting our findings from 
Ab7.16.4 + lapatinib-resistant transplant models and 
demonstrating their human pathological relevance.
Sequential application of Ab7.16.4 + BEZ235 following 
Ab7.16.4 + lapatinib is effective in reversing Ab7.16.4 + 
lapatinib resistance
Guided by the above finding that PI3K/mTOR path-
way is activated in lapatinib + trastuzumab-resistant 
breast cancers and Ab7.16.4 + lapatinib-resistant trans-
plant tumors, we tested whether PI3K/mTOR inhibitors 
are effective in overcoming resistance. We first isolated 
mammary tumor cells from two PTEN−/−/NIC mice (129F 
and 134F) who acquired resistance after 6 weeks of 
Ab7.16.4 + lapatinib combination treatment (129F.A + L.R 
and 134F.A + L.R). These primary cultures were resistant 
Figure 3 Sequential application of Ab7.16.4 + BEZ235 combination overcomes Ab7.16.4 + lapatinib resistance. (A) WST-1 
proliferation assay after 72 h of treatment with different drugs targeting PI3K and/or mTOR. Primary cells (129F.A + L.R and 
134F.A + L.R) from PTEN−/−/NIC mice treated with Ab + lapatinib over 4 weeks were used. ***P < 0.001, by one-way ANOVA 
and ***P < 0.001, by two-tailed t-test. (B) Western blot analysis of primary cells treated with the indicated drugs for 3 h. (C) 
Tumor volume measurements at different time points for transplant mice (782_L and 782_R) treated with Ab + lapatinib first 
and then with Ab + BEZ235 on day 12 upon resistance development. (D) Tumor volume fold change of transplant mice treat-
ed with vehicle (ctrl) or Ab7.16.4 + lapatinib or A + L/A + B. *P < 0.05, by two-tailed t-test. (E) Upper panel, WST-1 prolifera-
tion assay after 72 h treatment with the indicated drugs targeting PI3K and/or mTOR pathways in BT474.LapR cells. ***P < 
0.001, by two-tailed t-test. Lower panel, western blot analysis of signaling pathways in BT474.LapR cells upon treatment with 
different drugs or their combination for 3 h. (F) Survival analysis of the PTEN−/−/NIC mice treated with vehicle (ctrl) or Ab + 
lapatinib or A + L/A + B. The switch time for treatment was shown with a green arrow on the x-axis for the sequential therapy-
treated mice. P-value was determined by log-rank test. P = 0.0001 is between Ab7.16.4 + lapatinib and A + L/A + B sequential 
therapy.
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to Ab7.16.4 and/or lapatinib similar to the original 129F.
A + L.R and 134F.A + L.R tumors (Figure 3A). These 
primary culture cells were then treated with either GDC-
0941 (PI3K P110α/β-inhibitor) or RAD001 (mTORC1 
inhibitor) or BEZ235 (PI3K and mTOR dual inhibitor) in 
combination with Ab7.16.4. Clearly, BEZ235, alone or 
in combination with Ab7.16.4, was more effective than 
GDC-0941 + Ab7.16.4 or RAD001 + Ab7.16.4 in reduc-
ing cell viability, likely through simultaneous inhibition 
of p-AKT, p-S6 and p-4EBP (Figure 3A and 3B). Then, 
we tested whether BEZ235 + Ab7.16.4 may effectively 
inhibit Ab7.16.4 + lapatinib-resistant transplants in mice. 
Indeed, sequential application of Ab7.16.4 + BEZ235 (A 
+ B) after acquired resistance to Ab7.16.4 + lapatinib (A 
+ L) led to tumor stasis (Figure 3C and 3D) by reducing 
tumor cell proliferation (Figure 4C) but without signifi-
cant changes in apoptosis (Supplementary information, 
Figure S4). 
To test whether trastuzumab + BEZ235 also inhibits 
proliferation of the lapatinib + trastuzumab-resistant 
BT474.LapR human breast cancer cells, in which Akt 
and p-S6 are activated (Figure 2F), we treated the cells 
with lapatinib, BEZ235, GDC-0941, or RAD001 alone or 
in combination with trastuzumab. Although trastuzumab, 
lapatinib or their combination had no significant effect, 
BEZ235 or trastuzumab + BEZ235 inhibited BT474.
LapR cell growth significantly and more effectively than 
GDC-0941 + BEZ235 or RAD001 + BEZ235 (Figure 
3E, top). BEZ235 or trastuzumab + BEZ235 led to a 
complete blockage of Akt, S6 and 4EBP1 phosphoryla-
tion in BT474.LapR cells (Figure 3E, bottom) similar to 
its effect on Ab7.16.4 + lapatinib-resistant mouse mam-
mary tumor cells (129F.A + L.R and 134F.A + L.R). 
This promoted us to further test the sequential treatment 
strategy in PTEN−/−/NIC mice. We first treated mice with 
Ab7.16.4 + lapatinib, which initially inhibited tumor 
growth. After 4 weeks of treatment, tumor started to re-
grow, and we switched to Ab7.16.4 + BEZ235 combina-
tion treatment. This sequential regimen further increased 
survival (median survival of 86 days) significantly (P 
= 0.0001) compared to mice treated continuously with 
Ab7.16.4 + lapatinib (median survival of 75 days) or 
vehicle control (median survival of 50 days) (Figure 
3F). Altogether, these data indicated that trastuzumab + 
BEZ235 (or Ab7.16.4 + BEZ235 for mice) combination 
is effective in blocking proliferation of trastuzumab + 
lapatinib-resistant cells and Ab7.16.4 + lapatinib-resis-
tant PTEN−/−/NIC tumors, and sequential application of 
Ab + lapatinib followed by Ab + BEZ235 (A + L/A + B) 
increases the survival of PTEN−/−/NIC mice with highly 
aggressive tumors. 
BEZ235 enhances ErbB2 protein stability and activation
Although mice who had sequential (A + L/A + B) 
therapy had a significantly prolonged life-span, their tu-
mors later developed resistance. To conquer resistance 
to the sequential (A + L/A + B) therapy, we sought to 
dissect the underlying resistance mechanism. To this 
end, we treated transplant PTEN−/−/NIC tumors with 
Ab7.16.4 + lapatinib until tumor growth increased (re-
sistant) by day 12, then switched to Ab7.16.4 + BEZ235 
(Ab + BEZ) treatment until resistance developed seven 
days later on day 19 (Figure 4A and 4B). Notably, the 
resistant tumors had increased Ki-67+ cells compared 
to sensitive ones (Figure 4C). Then, we examined the 
PI3K/mTOR and ERK1/2 pathway activities in resistant 
versus sensitive tumors. Phosphorylation of Akt (S473), 
S6 (S235/236 and S240/244) and ERK1/2 (T202/Y204) 
was higher in resistant tumors compared to that in the 
sensitive ones (Figure 4D). Interestingly, p-Akt T308 and 
p-4EBP1 were not significantly different between resis-
tant and sensitive tumors (Figure 4D). The activation of 
multiple key signaling pathways led us to hypothesize 
that an upstream RTK could be involved in their activa-
tion and contribute to the resistance. Thus, we performed 
a phospho-RTK array to simultaneously detect the phos-
phorylation of 39 different mouse RTKs in tumor pro-
tein lysates. Remarkably, the only RTK with increased 
phosphorylation in resistant versus sensitive tumors was 
ErbB2/neu (Figure 4E). To verify the upregulation of 
ErbB2 phosphorylation and to test ErbB2 expression, we 
expanded our analyses of the ErbB2/p-ErbB2 levels in 
multiple A + L/A + B sequential treatment-resistant ver-
sus -sensitive mammary tumors using western blot. In-
deed, both the expression and phosphorylation of ErbB2/
neu were increased in dual sequential treatment-resistant 
Figure 4 Resistance to Ab7.16.4 + BEZ235 develops through activation of p-ErbB2 and downstream signaling. (A) Tumor 
volume measurements at different time points for transplant mice (782_L and 782_R) treated with Ab + lapatinib first and 
then with Ab + BEZ235 on day 12. Resistance to Ab + BEZ developed on day 19. (B) Representative pictures of tumors from 
mouse 782_L taken at shown time points after treatments indicated in A. (C) Ki-67 staining of the sensitive and resistant tu-
mors treated with A + L/A + B sequential therapy. ***P < 0.001, by two-tailed t-test. (D) Western blot analysis of A + L/A + B-
sensitive and -resistant tumors shown in C. (E) Top, phospho-RTK array comparing the phosphorylation of 39 RTKs in tumors 
from D. Bottom, quantification of p-ErbB2 signal intensity using Image J software. **P < 0.01, by two-tailed t-test. (F) Western 
blot analysis of A + L/A + B-sensitive and -resistant tumors shown in C. Actin was used as a loading control.
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tumors compared to that in sensitive tumors (Figure 4F).
To elucidate how ErbB2 phosphorylation is increased 
upon Ab7.16.4 + BEZ235 treatment in tumor cells re-
sistant to the A + L/A + B sequential targeted therapy, 
we treated BT474 parental (BT474.Par) and lapatinib + 
trastuzumab-resistant (BT474.LapR) cells with BEZ235 
alone or in combination with trastuzumab over a week. 
Treatment had no significant effect on ErbB2 expression 
or phosphorylation levels in either parental or resistant 
lines under regular 2-D cell culture (Supplementary in-
formation, Figure S5). However, when the cells were cul-
tured in 3-D with matrigel, ErbB2 expression and phos-
phorylation were dramatically increased upon BEZ235 
or BEZ235 + trastuzumab treatment in BT474.LapR 
cells, but not in BT474.Par cells shown by western blot 
(Figure 5A). Immunofluorescence staining also revealed 
that lapatinib + trastuzumab reduced ErbB2 phosphoryla-
tion, but BEZ235 + trastuzumab led to increased ErbB2 
phosphorylation despite effective inhibition of acinar 
proliferation (Figure 5B and Supplementary information, 
Figure S5B). Notably, ERBB2 mRNA level was not sig-
nificantly increased in response to BEZ235 or BEZ235 + 
trastuzumab treatment in 3-D cultured BT474.LapR cells 
(Supplementary information, Figure S5C). To investi-
gate how BEZ235 or BEZ235 + trastuzumab treatment 
increases ErbB2 protein level, we initially treated the 
BT474.LapR cells with DMSO or BEZ235 for a week in 
3-D culture, then treated cells with cycloheximide (CHX) 
to block protein synthesis for different times up to 24 h 
and detected ErbB2 protein levels by western blot. ErbB2 
protein decreased after 6 h of CHX treatment in DMSO-
treated BT474.LapR cells, while it did not decrease after 
almost 24 h under CHX treatment in BEZ235-treated 
BT474.LapR cells (Figure 5C and 5D). ErbB2 phos-
phorylation had a similar pattern. Consistent with the 
transplant tumor RTK array data, the EGFR protein was 
similarly degraded in both DMSO- and BEZ235-treated 
BT474.LapR cells although EGFR phosphorylation was 
stable with BEZ235 treatment due to increased ErbB2 
(Figure 5C). These data suggest that BEZ235 treatment 
specifically stabilizes ErbB2, leading to its increased 
phosphorylation and activation. Altogether, these data 
suggest that BEZ235 treatment-mediated ErbB2 protein 
stability and activation leads to the activation of multiple 
ErbB2 downstream pathways, thus conferring resistance 
to Ab + lapatinib/Ab + BEZ235 sequential treatment.
Marker-guided sequential treatment with A + L/A + B/A 
+ B + L doubles the life-span of PTEN−/−/NIC mice bear-
ing rapidly evolving aggressive mammary tumors
As ErbB2 expression and phosphorylation were 
increased in tumors resistant to Ab + lapatinib/Ab + 
BEZ235 dual sequential treatment, we next decided to 
add lapatinib, which inhibits ErbB2 kinase activity, back 
into the Ab + BEZ235 regimen to test whether the triple 
combination may overcome the resistance to sequential 
Ab + lapatinib/Ab + BEZ235 treatment. To this end, two 
donor PTEN−/−/NIC mice (254F and 315F) were first 
treated with Ab7.16.4 + lapatinib (A + L) for 4 weeks, 
followed by Ab7.16.4 + BEZ235 (A + B) treatment for 
another 4 weeks, and mammary tumor cells resistant to 
the sequential therapy (A + L/A + B.R) were isolated for 
primary culture (254F.A + L/A + B.R and 315F.A + L/
A + B.R). Both primary cells were resistant to treatment 
with either lapatinib or BEZ235 alone or in combination 
with Ab7.16.4. However, combinatorial application of 
lapatinib and BEZ235 with or without Ab7.16.4 signifi-
cantly inhibited proliferation of the A + L/A + B-resistant 
primary cells (Figure 5E). In both primary cells, although 
BEZ235 or Ab + BEZ treatment inhibited phosphoryla-
tion of S6 and 4EBP1 to a certain extent, Akt phosphory-
lation was not inhibited (Figure 5F). Furthermore, Erk1/2 
phosphorylation, downstream of ErbB2, was increased 
upon BEZ235 treatment. Remarkably, combinatorial ap-
plication of BEZ235 + lapatinib blocked Akt, S6, 4EBP1 
and ERK1/2 signaling downstream of ErbB2 (Figure 
5F). These results prompted us to apply the combina-
tion of Ab7.16.4, BEZ235, and lapatinib (A + B + L) in 
transplants resistant to Ab + lapatinib and Ab + BEZ235 
sequential treatment. The A + B + L triple combination 
treatment effectively reduced tumor volume (Figure 6A 
and 6B) not only by inhibiting cell proliferation (Figure 
6C), but also by increasing apoptosis (Figure 6D). We 
then tested the PI3K/mTOR and ERK1/2 pathway sta-
Figure 5 BEZ235 stabilizes ErbB2 protein and lapatinib + BEZ235 combination overcomes resistance to Ab + lapatinib/Ab 
+ BEZ235 in mouse primary cells. (A) Western blot analysis of cell lysates from BT474.Par and BT474.LapR cells grown in 
3-D culture under different treatments for a week. (B) Immunofluorescence staining of BT474.LapR cells grown in 3-D culture 
under different treatment conditions for a week. Scale bar indicates 50 µm. (C) Protein stability assay in BT474.LapR cells 
treated with DMSO or BEZ235 (for a week) in combination with CHX over 24 h. (D) Quantification of ErbB2 signal intensity 
from C. (E) WST-1 proliferation assay after 72 h treatment with the indicated drugs or combinations in primary cells (254F.A + 
L/A + B.R and 315F.A + L/A + B.R) derived from PTEN−/−/NIC mice treated with Ab + lapatinib for 4 weeks and then with Ab + 
BEZ235 for 4 weeks, by which time resistance had developed. ***P < 0.001, by one-way ANOVA. (F) Western blot analysis of 
254F.A + L/A + B.R and 315F.A + L/A + B.R primary cells after the indicated treatment for 3 h.
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tus in differently treated transplants and observed that 
sequential application of A + B + L after A + L/A + B 
treatment led to strong downregulation of Akt, S6 and 
ERK1/2 phosphorylation (Figure 6E). Finally, we ap-
plied the A + B + L after development of resistance to 
A + L/A + B sequential treatment in the original donor 
PTEN−/−/NIC mice. Triple sequential treatment (A + L 
followed by A + B, then followed by A + B + L, denoted 
as A + L/A + B/A + B + L) was highly effective in in-
creasing the survival of the PTEN−/−/NIC mice (median 
survival: 98 days) than both A + L (median survival: 75 
days, P < 0.0001 by log-rank test) or A + L/A + B (median 
survival: 86 days, P = 0.03 by log-rank test) treatments. 
The addition of the A + B + L triple combination after 
A + L/A + B sequential therapy doubled the life-span 
of mice bearing highly aggressive mammary tumors by 
increasing the median survival time from 45 days to 98 
days (Figure 6F) and substantially reduced tumor size 
and multiplicity (Figure 6G). We also tested whether 
sequential treatment was superior to treatment with 
Ab7.16.4 + lapatinib + BEZ235 from the beginning (see 
Figure 6F, “A + L + B”). Sequential treatment showed a 
trend towards superior survival compared to A + L + B (P 
= 0.067; median survival 84.5 versus 98 days). Notably, 
two mice in the A + L + B triple combination had to be 
sacrificed around day 40 (Figure 6F) due to severe toxic 
responses including significant weight loss (Figure 7A 
and 7B). Thus sequential treatment maximized survival 
while minimizing toxicity compared to all other treat-
ments tested (Figure 7C). Taken together, these data 
clearly demonstrate that biomarker-guided, sequential 
application of targeted therapies can effectively target 
and reprogram the  signaling networks in cancer evolving 
resistance, create cancer vulnerabilities, and substantially 
increase the survival of mice bearing highly aggressive 
therapy-refractory tumors.
Discussion
In the current metastatic or late-stage therapy set-
tings even the most successful targeted agents can only 
prolong the survival of patients for a limited time. De 
novo or acquired resistance to therapies as well as over-
treatment due to lack of robust biomarkers are the main 
problems associated with treatment failure. Trastuzumab, 
the mainstay therapy for ErbB2-positive patients, has 
an initial clinical response in only 12%-34% of patients, 
and the majority of these patients acquire resistance to 
the drug within one year [24]. Therefore, there is an 
urgent need for identification of biomarkers to choose 
patients with higher potential of response and novel tar-
gets to reverse resistance. Here, we designed a sequen-
tial targeted therapy strategy guided by identification 
of resistance mechanisms and resulting biomarkers. We 
tested the strategy in a highly aggressive trastuzumab-
resistant transgenic animal model, ErbB2-overexpressing 
human breast cancer and primary culture mouse tumor 
cells. Here, we demonstrated that the biomarker-guided, 
sequential application of different targeted therapy com-
binations effectively targets the signaling networks in 
cancer evolving therapy resistance to better inhibit tumor 
progression than using a single targeted therapy combi-
nation throughout the course of the treatment. 
The role of PTEN loss and the resulting activation 
of PI3K/Akt pathway has been well characterized in de 
novo resistance of breast cancer cells to trastuzumab [9, 
10]. However, PTEN’s role in lapatinib resistance has 
been controversial. Loss of PTEN in BT474 cells by 
shRNAs was shown to lead to lapatinib resistance both 
in vitro and in vivo [25]. Similarly, activation of PI3K 
signaling resulting from PTEN loss or PI3K mutations 
has been reported for both trastuzumab and lapatinib re-
sistance in patients [26]. On the other hand, the response 
to lapatinib of ErbB2-overexpressing PTEN-knockdown 
BT474 and AU565 cell lines, and of patients with in-
flammatory breast cancers is independent of PTEN status 
[27]. Interestingly, low PTEN level was associated with a 
higher pathological response to lapatinib in breast cancer 
patients [21]. Our study clearly demonstrates that PTEN 
loss does not confer lapatinib resistance in the PTEN−/−/
Figure 6 Marker-guided sequential treatment doubles the life-span of PTEN−/−/NIC mice bearing highly aggressive mammary 
tumors. (A) Tumor volume measurements at different time points for transplant mice treated with Ab + lapatinib (A + L) first, 
then with Ab + BEZ235 (A + B) on day 12, and Ab + lapatinib + BEZ235 (A + L + B) on day 19 upon resistance development. (B) 
Representative images of a tumor from transplant mouse 782_L taken before and after A + L + B treatment. (C) Ki-67 staining 
of transplant tumors treated with A + L/A + B/A + L + B sequential therapy compared to Ab + lapa treatment or vehicle. **P < 
0.01, ***P < 0.001, by two-tailed t-test. (D) TUNEL staining of tumors from C. ***P < 0.001, by two-tailed t-test. (E) Immuno-
histochemical (IHC) staining of p-Akt, p-S6 and p-ERK1/2 of transplants treated with A + L/A + B/A + L + B sequential therapy 
compared to vehicle (Ctrl)-treated mice. (F) Survival analysis of the PTEN−/−/NIC mice treated with vehicle, Ab + lapatinib (A + 
L), Ab + lapatinib + BEZ235 (A + L + B) or A + L/A + B/A + B + L sequential therapy. P-value was determined by log-rank test. 
P < 0.001 is between Ab7.16.4 + lapatinib and A + L/A + B/A + B + L sequential therapy. (G) Tumor weight (mean ± SEM) of 
mice treated with vehicle (Ctrl) or A + L/A + B/A + L + B therapy. ***P < 0.001 by two-tailed t-test.
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NIC immune-competent mice with mammary gland-
targeted ErbB2 overexpression and PTEN knockout 
(Figure 1E). Rather, when combined with trastuzumab, 
lapatinib increased the survival of mice by reducing the 
proliferation of cancer cells (Figure 1E-1G). Our data 
also showed that although PTEN loss confers de novo 
trastuzumab resistance, trastuzumab + lapatinib are more 
effective in tumor inhibition than lapatinib alone, indicat-
ing that trastuzumab should still be used with lapatinib 
to treat patients with PTEN-low tumors. Recently, a 
clinical study similarly found that lapatinib combined 
with trastuzumab was more effective (4.5 months overall 
Figure 7 The effects of treatments on mouse weight and appearance, and the model explaining the superiority of the 
biomarker-guided, sequential combinatorial targeted therapies. (A) Mouse weight measurements after treatment of the 
PTEN−/−/NIC mice with the indicated agents for 10 days (20 days in the case of sequential A + L/A + B). Vehicle, lapatinib, 
Ab7.16.4 + lapatinib (A + L), Ab7.16.4 + BEZ235 (A + B), Ab7.16.4 + lapatinib followed by Ab7.16.4 + BEZ235 (A + L/A + B), 
and Ab7.16.4 + lapatinib + BEZ235 (A + L + B). ns, not significant (P > 0.05) and *P < 0.05, by two-tailed t-test. A + L + B 
treatment led to weight loss. (B) Pictures of the mice treated with Ab7.16.4 + lapatinib (Ab + Lapa) or Ab7.16.4 + lapatinib + 
BEZ235 (Ab + Lapa + BEZ) from (A). (C) Model showing how biomarker-guided, sequential combinatorial targeted therapies 
maximize mouse survival in rapidly evolving tumors while reducing toxicity compared to current clinical practices.
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survival advantage) than lapatinib alone for patients who 
had progressive disease on trastuzumab treatment [20].
Our study shows that development of resistance to 
lapatinib involved the activation of the PI3K and mTOR 
pathways in the PTEN−/−/NIC mouse model, the human 
BT474.LapR cell lines with acquired resistance, and im-
portantly, also in breast cancer patients treated with lapa-
tinib. Several studies have indicated the role of the PI3K 
and/or mTOR pathways in acquired lapatinib resistance 
and have suggested using PI3K or mTOR inhibitors in 
combination with lapatinib [25, 28]. However, these 
studies tested the combination either in cell culture or 
in xenograft models without considering toxicity, which 
is often a major obstacle in successful translation to the 
clinic. For example, combinatorial inhibition of PI3K 
and MAPK pathways in various advanced tumors led to 
better efficacy but higher toxicity compared to individual 
treatments [16]. Similarly, combinatorial treatment of 
mice bearing ovarian tumor xenografts with GNE493 
(mTOR inhibitor) and ABT-737 (Bcl-2 inhibitor) led to 
5% to 20% loss of body weight after 7 days of treatment 
[29]. We observed that triple combination treatment of 
Ab7.16.4 + BEZ235 + lapatinib for 10 days induced up 
to 20% loss of body weight and rough coat in some of 
the PTEN−/−/NIC mice (Figure 7A and 7B). However, 
sequential treatment of Ab7.16.4 + lapatinib for 10 days 
followed by Ab7.16.4 + BEZ235 for another 10 days did 
not induce significant weight loss. Clearly, sequential 
application of various targeted therapies may be a better 
strategy to manage both tumor growth and side-effects 
than simultaneous application of all drugs in the course 
of treatment. Accordingly, our strategy was to first apply 
Ab7.16.4 + lapatinib, then Ab7.16.4 + BEZ235, and fi-
nally Ab7.16.4 + BEZ235 + lapatinib only after PTEN−/−/
NIC tumors developed resistance to Ab7.16.4 + BEZ235 
for maximum tumor inhibition and minimum toxicity. 
Additionally, this sequential therapy can also generate 
cancer vulnerabilities to be effectively targeted with the 
subsequent agent. Supporting this idea, it was recently 
shown that sequential, but not simultaneous, application 
of an EGFR inhibitor and chemotherapy led to apoptosis 
of triple negative breast cancer cell lines by rewiring the 
DNA damage network resulting in activation of Cas-
pase-8 in vitro [30]. Similarly, in our study, we showed 
for the first time that Ab7.16.4 + lapatinib combination 
reprogrammed the cancer cell signaling network and 
led to activation of the PI3K/mTOR pathway, which 
was successfully inhibited by subsequent application of 
Ab7.16.4 + BEZ235 in vivo. 
Little is known about the mechanisms of resistance to 
BEZ235 treatment. Recently, two studies suggested the 
involvement of the MYC oncogene, which is downstream 
of the PI3K/mTOR pathway [31]. First, an unbiased 
screen showed that MYC conferred resistance to BEZ235 
in the human mammary epithelial cell (HMEC) line 
MCF-10A, and that BEZ235-resistant human cell lines 
had higher c-MYC gene copy number compared to their 
sensitive counterparts [32]. Second, MYC and eIF4E 
amplification was identified in BEZ235-resistant HMECs 
in addition to genome-wide copy number alteration [33]. 
Here, we did not observe any change in MYC mRNA 
level in our BT474.Par or lapatinib-resistant BT474.Lap.
R cells upon long-term BEZ235 treatment (Supplemen-
tary information, Figure S6A). c-Myc protein was also 
not increased after long-term treatment with BEZ235 in 
BT474 LapR cells (Supplementary information, Figure 
S6B). Rather, we observed a consistent increase in ErbB2 
expression and phosphorylation in both mice and human 
breast cancer cells grown in 3-D culture with sequential 
lapatinib and BEZ235 treatment. The increase in ErbB2 
phosphorylation led to an increase in downstream activa-
tion of Erk1/2, Akt and S6 which provided signals nec-
essary for survival and proliferation of the cancer cells. 
As BEZ235 stabilizes ErbB2 and leads to its activation, 
the combination of ErbB2-targeting agents and BEZ235 
reduced the phosphorylation of ErbB2 and downstream 
kinases and led to an increase in apoptosis and a decrease 
in cell proliferation at the expense of higher toxicity. 
Our findings bring novel insights into the mechanisms of 
BEZ235 resistance that may guide future development 
of strategies to reverse the resistance without increasing 
toxicity.
In conclusion, we propose a novel strategy of using 
biomarkers in cancer evolving therapy resistance to guide 
the application of various targeted therapies in a sequen-
tial manner, instead of simultaneously, to induce cancer 
vulnerability and effectively block tumor progression. 
We have validated this rational approach in multiple ani-
mal models and by using patient data. Our data demon-
strate that sequential application of lapatinib and BEZ235 
in combination with trastuzumab led to a doubling of the 
life-span of PTEN−/−/NIC mice bearing highly aggres-
sive, treatment-refractory mammary tumors. Importantly, 
the mouse model that we used (PTEN−/−/NIC) reflects the 
intratumoral heterogeneity of breast cancer as PTEN loss 
is highly heterogeneous (determined by IHC), indicating 
that some parts of the tumor may be primarily driven by 
ErbB2/neu while others are driven by PTEN loss as well 
(Supplementary information, Figure S7). Similar hetero-
geneity has also been reported in other GEM models [34, 
35]. Additionally, our experimental approach of testing 
drugs in a time-efficient and robust manner using trans-
plantation in immune-competent mice could be utilized 
for setting up synchronous mouse co-clinical trials to 
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study the resistance mechanisms of patients in real time, 
similar to the elegant work done in lung cancer in which 
the mouse trial was used to predict the outcome of an 
on-going human clinical trial [36]. Notably, our findings 
may potentially change the current clinical management 
of patients having highly aggressive ErbB2-overexpress-
ing trastuzumab-resistant breast cancers as the targeted 
therapies used in our study are either FDA approved or 
in clinical trials. More importantly, this strategy of us-
ing biomarker-guided, sequential, combinatorial targeted 
therapies in rapidly evolving tumors can also be rapidly 
translated into the clinic for patients with other cancer 
types receiving different targeted therapies to significant-
ly reduce cancer deaths.
Materials and Methods
Transgenic animal model and syngeneic tumor transplanta-
tion
MMTV-NIC (Neu-IRES-Cre) mice [37] were interbred with 
Flox-PTEN mice to generate HER2/neu-overexpressing PTEN 
homozygous loss (PTEN−/−/NIC) mice [12]. For tumor transplan-
tation, the donor PTEN−/−/NIC tumors were cut into quasi-equal 
pieces of 3-5 mm in diameter after sacrificing donor mice. Recipi-
ent FVB mice were anesthetized, the skin was incised and donor 
tumors were transplanted into both left and right MFP of the re-
cipient mice. Incisions were closed using wound clips which were 
removed after 7 days. Tumor size was measured 3-5 days later and 
treatment was started when tumors reached 4-5 mm. Tumors were 
measured using calipers and volume was calculated as length × 
width2/2. Tumor volume fold changes were calculated by taking 
the ratio of most recent measurements to previous measurements 
for the same tumor. All tumor measurements were included in the 
analysis. All animal studies were approved by the MD Anderson 
Cancer Center Institutional Animal Care and Use Committee.
Animal treatment
mAb7.16.4 hybridoma was a kind gift from Dr Mark Greene. 
PTEN−/−/NIC mice were randomized to treatment groups when 
the first palpable tumor was 3-5 mm in diameter. 7.16.4 mAb was 
administered intraperitoneally at 2 mg/kg body weight every 3 
days in PBS as described previously [13]. We treated the original 
donor mice with lapatinib (LC Laboratories, Woburn, MA, USA) 
or BEZ235 (Novartis, Basel, Switzerland) daily at 100 mg/kg or 
50 mg/kg, respectively, in vehicle (0.5% wt/vol hydroxypropyl-
methylcellulose with 0.1% vol/vol Tween 20) via daily oral ga-
vage. Mice were sacrificed either after treatment for 3 weeks or 
when the tumor size reached the institutional euthanasia criteria, 
and tumors were harvested and weighed. 
Cell culture and primary cell preparation
BT474 m1 cells were a gift from Dr Dajun Yang. Lapatinib-
resistant cells were established by exposure of the cells to 2.1 µM 
lapatinib for > 9 months. BT474.shPTEN cells were described pre-
viously [14]. Primary cells from mice were prepared by incubating 
minced tissue in growth medium containing collagenase A (Roche, 
Mannheim, Germany) and hyaluronidase (Sigma, St Louis, MO, 
USA) for 6 h at 37 °C with continuous mixing. After centrifuga-
tion and removal of debris and blood cells, cells were plated and 
grown for 48 h. These cells were then used for viability and west-
ern blot assays without further passaging. 
In vitro drug treatment and cell viability assay
Primary mouse cells or human BT474.LapR or BT474.shPTEN 
cells were seeded in 96-well plates 24 h before the assay. After 
treatment of the cells with trastuzumab (2 µg/ml), Ab7.16.4 (5 µg/
ml for mouse primary cells), lapatinib (1 µM), BEZ235 (500 nM), 
GDC-0941 (1 µM) or RAD001 (50 nM) for 72 h, cells were incu-
bated with 20 µl of WST-1 (Roche, Penzberg, Germany) in 200 µl 
of final volume for 4 h. Absorbance at 450 nm was measured and 
percentage of viability was calculated. 
3-D morphogenesis assay
BT474.Par and BT474.LapR cells were seeded into 8-chamber 
slides (BD Biosciences, San Jose, CA, USA) coated with 40 µl of 
growth factor-reduced matrigel (BD Biosciences). 3-D structures 
were fixed and stained as previously described [38]. For mRNA 
or protein analysis, cells were seeded in 2% Matrigel into 60-mm 
dishes coated with 4 ml of polyHEMA (Sigma, St Louis, MO, 
USA). 
Protein stability sssay
BT474.LapR cells were grown in 3-D culture under DMSO or 
BEZ235 treatment over a week, and CHX (5 µg/ml; Calbiochem) 
was given for 0, 2, 4, 6, 12 or 24 h followed by western blot analy-
sis. 
Western blot and immunoprecipitation
Tumor protein extracts were prepared by homogenizing sam-
ples in tissue lysis buffer (10 mmol/l sodium phosphate (pH 7.3), 
154 mmol/l NaCl, 5% sodium deoxycholate, 1% SDS) using a tis-
sue grinder, followed by centrifugation. Western blot was done as 
previously described [14, 39]. List of antibodies used in this study 
is given in Supplementary information, Table S4.
RPPA and p-RTK array
Protein lysate for RPPA was prepared according to MD Ander-
son RPPA Core instructions (available online) and run by the Core. 
Quantification of mouse phospho RTK arrays (ARY014, R&D, 
Minneapolis, MN, USA) was done with ImageJ (National Insti-
tutes of Health).
RNA extraction and quantitative real-time RT-PCR
RNA was isolated using Trizol (Invitrogen) and reverse 
transcribed with iScriptTM cDNA synthesis kit (Biorad, Her-
cules, CA, USA). qRT-PCR was performed with iQ SYBR 
Green Supermix (Biorad, Hercules, CA) and StepOneP-
lus (Applied Biosystems, Grand Island, NY, USA) instru-
ment . The genes analyzed were ERBB2 , MYC and 18S 
(used as housekeeping control). Primer sequences were: 
ERBB2_forw_5′-GGGAAACCTGGAACTCACCT-3′ and 
ERBB2_rev_5 ′ -CCCTGCACCTCCTGGATA-3 ′ ; MYC_
forw_5′-CCTGGTCAAGAAGCATTTCAA-3′ and MYC_
rev_5 ′ -GCCCCAAAGATGAGGAGTATC-3 ′ ; and 18S_
forw_5′-AACCCGTTGAACCCCATT-3′ and 18S_rev_5′-
CCATCCAATCGGTAGTAGCG-3′. Data were analyzed with the 
Sequential targeted therapy to overcome resistance
558
npg
 Cell Research | Vol 24 No 5 | May 2014
delta-delta CT method.
Microarray data analysis of patient tumors
Neoadjuvant trastuzumab + chemotherapy (n = 45) patient gene 
expression data [17] were classified into two groups: trastuzumab-
sensitive/high PTEN (n = 7) and trastuzumab-resistant/low PTEN 
(n = 7) according to their pathological response and PTEN mRNA 
expression. Differentially expressed genes with fold change > 
2 were analyzed by IPA of canonical pathways. Pre- and post-
lapatinib treatment gene expression data from 13 patients (nine 
responders) [21] were analyzed by GSEA [22].
Immunohistochemistry and TUNEL staining 
IHC and TUNEL staining were performed as described previ-
ously [13] using antibodies for p-Akt (1:400), Ki-67 (DAKO, 
1:200), p-S6 (1:400), and p-Erk (1:200).
Statistical analyses
Statistical differences were determined by 2-tailed t-test, one-
way ANOVA or log-rank test. The GraphPad Prism 6 Program 
(GraphPad Software, La Jolla, CA, USA) was used to perform all 
statistical analyses. P < 0.05 was considered statistically signifi-
cant.
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